
Overall response rates to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.

This study protocol aims to address this unmet clinical need by evaluating possible increased ICI effectiveness with the addition of a prospective immunosensitizing strategy and generating molecular and cellular immune-responsive models to define biomarkers predictive of treatment response and improve patient selection for ICIs in A/R/M HNSCC.